Authors

Washington University School of Medicine in St. Louis

Latest:

Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.

Dietmar Berger, Global Head of Development, Sanofi

Latest:

Advancing Care in Metastatic Breast Cancer

Sponsored Content by SANOFI

Danielle K. DePalo, MD

Latest:

Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit Metastases

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Steven Maron, MD, MSS

Latest:

Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric Cancer

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Vilde D. Haakensen, MD, PhD

Latest:

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Benjiman Saylor

Latest:

Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC

Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.

UCLA Health Jonsson Comprehensive Cancer Center

Latest:

UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in Mice

UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling

Suzanne Trudel, MSc, MD

Latest:

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Peter Forsyth, MD

Latest:

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

UC Davis Health

Latest:

Genetic “Trojan Horse” Selectively Kills Cancer Cells Linked to Kaposi’s Sarcoma

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

Yael Cohen, MD

Latest:

Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple Myeloma

Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Cameron James Oswalt MD

Latest:

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Renold Capocasale

Latest:

Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 Vaccines

Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.

Francis Worden, MD

Latest:

Exploring Real-World Evidence Presented at ATA 2023

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Hayder M. Saeed, MD, Moffitt Cancer Center

Latest:

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Noam VanderWalde, MD, MS

Latest:

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Jung-Yun Lee, MD, PhD

Latest:

Dr Lee on Tremelimumab Plus Durvalumab in Ovarian Cancer

Jung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.

Kami Maddocks, MD, Ohio State University Medical Center

Latest:

Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cedars-Sinai Cancer

Latest:

Missing a Rare Cause of Hereditary Cancer

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.